BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 29.6] [Reference Citation Analysis]
Number Citing Articles
1 Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU. Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25:390-9. [PMID: 31146508 DOI: 10.3350/cmh.2018.0103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
2 Gao R, Cai C, Gan J, Yang X, Shuang Z, Liu M, Li S, Tang H. miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells. Oncotarget 2015;6:6014-28. [PMID: 25714026 DOI: 10.18632/oncotarget.3338] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
3 Leong K, Kuppasani K, Pyrsopoulos N. Atrial tumor thrombus: A rare complication of hepatocellular carcinoma. Journal of the American Academy of Physician Assistants 2019;32:23-6. [DOI: 10.1097/01.jaa.0000552723.65316.80] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Huang Y, Zheng J, Chen D, Li F, Wu W, Huang X, Wu Y, Deng Y, Qiu F. Transcriptome profiling identifies a recurrent CRYL1-IFT88 chimeric transcript in hepatocellular carcinoma. Oncotarget 2017;8:40693-704. [PMID: 28489570 DOI: 10.18632/oncotarget.17244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Simón Serrano S, Tavecchio M, Grönberg A, Sime W, Jemaà M, Moss S, Gregory MA, Gallay P, Elmér E, Hansson MJ, Massoumi R. Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3041. [PMID: 34207224 DOI: 10.3390/cancers13123041] [Reference Citation Analysis]
6 Cheon GJ, Kim KH, Park JY, Lee D, Jang H, Kwak JH, Choi KM, Kim JH, Hwang GS, Ham J, Lee S, Eom D, Kang KS. Caspase-mediated Apoptotic Effects of Diol-type Ginseng Sapogenins on Human Hepatoma Cell Lines. Bull Korean Chem Soc 2015;36:431-4. [DOI: 10.1002/bkcs.10074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res 2019;11:1391-400. [PMID: 30863150 DOI: 10.2147/CMAR.S190545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
8 Chen L, Guan H, Gu C, Cao Y, Shao J, Wang F. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL. Tumor Biol 2016;37:2497-507. [DOI: 10.1007/s13277-015-4071-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
9 Pant K, Saraya A, Venugopal SK. Oxidative stress plays a key role in butyrate-mediated autophagy via Akt/mTOR pathway in hepatoma cells. Chem Biol Interact 2017;273:99-106. [PMID: 28600122 DOI: 10.1016/j.cbi.2017.06.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
10 Di Paola M, Quarta A, Conversano F, Sbenaglia EA, Bettini S, Valli L, Gigli G, Casciaro S. Human Hepatocarcinoma Cell Targeting by Glypican-3 Ligand Peptide Functionalized Silica Nanoparticles: Implications for Ultrasound Molecular Imaging. Langmuir 2017;33:4490-9. [DOI: 10.1021/acs.langmuir.7b00327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
11 Huang T, Xu S, Deo R, Ma A, Li H, Ma K, Gan X. Targeting the Ca2+/Calmodulin-dependent protein kinase II by Tetrandrine in human liver cancer cells. Biochemical and Biophysical Research Communications 2019;508:1227-32. [DOI: 10.1016/j.bbrc.2018.12.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
12 Chou LF, Chen CY, Yang WH, Chen CC, Chang JL, Leu YL, Liou MJ, Wang TH. Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression. Biomolecules 2019;10:E20. [PMID: 31877715 DOI: 10.3390/biom10010020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Verloh N, Jensch I, Lürken L, Haimerl M, Dollinger M, Renner P, Wiggermann P, Werner JM, Zeman F, Stroszczynski C, Beyer LP. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors. Radiol Oncol 2019;53:116-22. [PMID: 30840591 DOI: 10.2478/raon-2019-0011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 Chen R, Gao Z, Wu X, Campbell JL, Zhang P, Chen B. Hepatocellular carcinoma presenting as thoracic spinal canal metastasis with no clinical primary foci: A report of a rare case and review of the literature. Oncol Lett 2015;10:2333-6. [PMID: 26622846 DOI: 10.3892/ol.2015.3569] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Kim J, Jung KH, Yan HH, Cheon MJ, Kang S, Jin X, Park S, Oh MS, Hong SS. Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma. BMC Complement Altern Med 2018;18:147. [PMID: 29739391 DOI: 10.1186/s12906-018-2217-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
16 Chowdhury SM, Lee T, Bachawal SV, Devulapally R, Abou-Elkacem L, Yeung TA, Wischhusen J, Tian L, Dahl J, Paulmurugan R, Willmann JK. Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma. J Control Release 2018;281:19-28. [PMID: 29758233 DOI: 10.1016/j.jconrel.2018.05.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
17 Yang X, Song H, Zi Z, Kou J, Chen S, Dai Y, Wang J, Yuan L, Gao K. Circ_0005075 promotes hepatocellular carcinoma progression by suppression of microRNA-335. J Cell Physiol 2019;234:21937-46. [PMID: 31054187 DOI: 10.1002/jcp.28757] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
18 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Lim ZW, Varma VB, Ramanujan RV, Miserez A. Magnetically responsive peptide coacervates for dual hyperthermia and chemotherapy treatments of liver cancer. Acta Biomater 2020;110:221-30. [PMID: 32422317 DOI: 10.1016/j.actbio.2020.04.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
20 Hong J, Kim S, Lin PC. Interleukin-33 and ST2 Signaling in Tumor Microenvironment. J Interferon Cytokine Res 2019;39:61-71. [PMID: 30256696 DOI: 10.1089/jir.2018.0044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
21 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ramani NS, Green LK. Metastatic hepatocellular carcinoma to the bone diagnosed by fine needle aspiration in a veteran population. Diagn Cytopathol 2022. [PMID: 35403368 DOI: 10.1002/dc.24961] [Reference Citation Analysis]
23 Riedel R, Pérez-Pérez A, Carmona-Fernández A, Jaime M, Casale R, Dueñas JL, Guadix P, Sánchez-Margalet V, Varone CL, Maymó JL. Human amniotic membrane conditioned medium inhibits proliferation and modulates related microRNAs expression in hepatocarcinoma cells. Sci Rep 2019;9:14193. [PMID: 31578445 DOI: 10.1038/s41598-019-50648-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
24 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
25 Yan J, Shu M, Li X, Yu H, Chen S, Xie S. Prognostic Score-based Clinical Factors and Metabolism-related Biomarkers for Predicting the Progression of Hepatocellular Carcinoma. Evol Bioinform Online 2020;16:1176934320951571. [PMID: 33013158 DOI: 10.1177/1176934320951571] [Reference Citation Analysis]
26 Khuanphram N, Taya S, Kongtawelert P, Wongpoomchai R. Sesame Extract Promotes Chemopreventive Effect of Hesperidin on Early Phase of Diethylnitrosamine-Initiated Hepatocarcinogenesis in Rats. Pharmaceutics 2021;13:1687. [PMID: 34683980 DOI: 10.3390/pharmaceutics13101687] [Reference Citation Analysis]
27 Fekri A, Keshk EM, Khalil AM, Taha I. Synthesis of novel antioxidant and antitumor 5-aminopyrazole derivatives, 2D/3D QSAR, and molecular docking. Mol Divers 2021. [PMID: 33683569 DOI: 10.1007/s11030-021-10184-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Zhang F, Yang J, Nezami N, Laage-Gaupp F, Chapiro J, De Lin M, Duncan J. Liver Tissue Classification Using an Auto-context-based Deep Neural Network with a Multi-phase Training Framework. Patch Based Tech Med Imaging (2018). 2018;11075:59-66. [PMID: 32432233 DOI: 10.1007/978-3-030-00500-9_7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
29 Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget 2016;7:83806-16. [PMID: 27566566 DOI: 10.18632/oncotarget.11514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
30 Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M. Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. Int J Mol Sci 2019;20:E1406. [PMID: 30897788 DOI: 10.3390/ijms20061406] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
31 Chang TT, Ho CH. Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma. PLoS One 2020;15:e0238251. [PMID: 32845921 DOI: 10.1371/journal.pone.0238251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen CY, Chen CC, Chuang WY, Leu YL, Ueng SH, Hsueh C, Yeh CT, Wang TH. Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells. Front Oncol 2020;10:216. [PMID: 32158695 DOI: 10.3389/fonc.2020.00216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sammar M, Abu-Farich B, Rayan I, Falah M, Rayan A. Correlation between cytotoxicity in cancer cells and free radical-scavenging activity: In vitro evaluation of 57 medicinal and edible plant extracts. Oncol Lett 2019;18:6563-71. [PMID: 31819777 DOI: 10.3892/ol.2019.11054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
34 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
35 Gu T, Ge Y, Song Y, Fu Z, Zhang Y, Wang G, Shao S, Wen T. Hepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma. Scand J Clin Lab Invest 2015;75:621-7. [PMID: 26305424 DOI: 10.3109/00365513.2015.1050689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
36 Yang Y, Liao Y, Gui YP, Zhao L, Guo LB. GL-V9 reverses adriamycin resistance in hepatocellular carcinoma cells by affecting JNK2-related autophagy. Chin J Nat Med 2020;18:491-9. [PMID: 32616189 DOI: 10.1016/S1875-5364(20)30059-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Tian G, Yang S, Yuan J, Threapleton D, Zhao Q, Chen F, Cao H, Jiang T, Li L. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis. BMJ Open. 2018;8:e021269. [PMID: 30341113 DOI: 10.1136/bmjopen-2017-021269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
38 Tang N, Dou X, You X, Li Y, Li X, Liu G. Androgen Receptors Act as a Tumor Suppressor Gene to Suppress Hepatocellular Carcinoma Cells Progression via miR-122-5p/RABL6 Signaling. Front Oncol 2021;11:756779. [PMID: 34745992 DOI: 10.3389/fonc.2021.756779] [Reference Citation Analysis]
39 Jeganathan S, Budziszewski E, Bielecki P, Kolios MC, Exner AA. In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. J Control Release 2020;324:146-55. [PMID: 32389777 DOI: 10.1016/j.jconrel.2020.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Wei J, Sun Z, Shi L, Hu S, Liu D, Wei H. Molecular Mechanism of Chrysin in Hepatocellular Carcinoma Treatment Based on Network Pharmacology and in Vitro Experiments. Natural Product Communications 2021;16:1934578X2110672. [DOI: 10.1177/1934578x211067294] [Reference Citation Analysis]
41 Bai N, Peng E, Qiu X, Lyu N, Zhang Z, Tao Y, Li X, Wang Z. circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346. J Exp Clin Cancer Res 2018;37:172. [PMID: 30053867 DOI: 10.1186/s13046-018-0838-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 18.3] [Reference Citation Analysis]
42 Worlikar T, Mendiratta-Lala M, Vlaisavljevich E, Hubbard R, Shi J, Hall TL, Cho CS, Lee FT, Greve J, Xu Z. Effects of Histotripsy on Local Tumor Progression in an in vivo Orthotopic Rodent Liver Tumor Model. BME Front 2020;2020:9830304. [PMID: 34327513 DOI: 10.34133/2020/9830304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Odabas G, Cetin M, Turhal S, Baloglu H, Sayan AE, Yagci T. Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:4040787. [PMID: 30327758 DOI: 10.1155/2018/4040787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Ye F, Jia D, Lu M, Levine H, Deem MW. Modularity of the metabolic gene network as a prognostic biomarker for hepatocellular carcinoma. Oncotarget 2018;9:15015-26. [PMID: 29599922 DOI: 10.18632/oncotarget.24551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Bi Y, Jiang H, Wang P, Song B, Wang H, Kong X, Li Z. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. Oncotarget 2017;8:52866-76. [PMID: 28881778 DOI: 10.18632/oncotarget.17905] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
46 Lafnoune A, Lee SY, Heo JY, Gourja I, Darkaoui B, Abdelkafi-Koubaa Z, Chgoury F, Daoudi K, Chakir S, Cadi R, Mounaji K, Srairi-Abid N, Marrakchi N, Shum D, Seo HR, Oukkache N. Anti-Cancer Effect of Moroccan Cobra Naja haje Venom and Its Fractions against Hepatocellular Carcinoma in 3D Cell Culture. Toxins (Basel) 2021;13:402. [PMID: 34199838 DOI: 10.3390/toxins13060402] [Reference Citation Analysis]
47 Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3:732-736. [PMID: 27275318 DOI: 10.3889/oamjms.2015.111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
48 Chicco D, Oneto L. Computational intelligence identifies alkaline phosphatase (ALP), alpha-fetoprotein (AFP), and hemoglobin levels as most predictive survival factors for hepatocellular carcinoma. Health Informatics J 2021;27:1460458220984205. [PMID: 33504243 DOI: 10.1177/1460458220984205] [Reference Citation Analysis]
49 Fu XT, Shi YH, Zhou J, Peng YF, Liu WR, Shi GM, Gao Q, Wang XY, Song K, Fan J, Ding ZB. Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. Infect Agent Cancer 2017;12:28. [PMID: 28559922 DOI: 10.1186/s13027-017-0137-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
50 Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, Turkmen C. Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT. Clin Nucl Med. 2019;44:702-706. [PMID: 31348076 DOI: 10.1097/rlu.0000000000002701] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
51 Yang L, Yuan Z, Zhang Y, Cui Z, Li Y, Hou J, Liu X, Liu Z, Shi R, Tian Q, Wang J, Wang L. MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 2021;87:125-34. [PMID: 33141330 DOI: 10.1007/s00280-020-04182-1] [Reference Citation Analysis]
52 Miao JF, Peng YF, Chen S, Gao WJ, Yang QX, Zhu P, Guo J, Tao J, Luo L, Zhang Y, Ling Y. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects. Eur J Pharmacol 2018;824:78-88. [PMID: 29428472 DOI: 10.1016/j.ejphar.2018.02.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
53 Numata Y, Akutsu N, Ishigami K, Koide H, Wagatsuma K, Motoya M, Sasaki S, Nakase H. Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma. Biochemistry and Biophysics Reports 2022;30:101270. [DOI: 10.1016/j.bbrep.2022.101270] [Reference Citation Analysis]
54 Salgado SM, Gaidhane M, Kahaleh M. Endoscopic palliation of malignant biliary strictures. World J Gastrointest Oncol 2016; 8(3): 240-247 [PMID: 26989459 DOI: 10.4251/wjgo.v8.i3.240] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 He C, Zhang Y, Lin X. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. J Gastrointest Surg 2018;22:989-97. [PMID: 29435900 DOI: 10.1007/s11605-018-3703-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 Zhao X, Liu W, Liu B, Zeng Q, Cui Z, Wang Y, Cao J, Gao Q, Zhao C, Dou J. Exploring the underlying molecular mechanism of liver cancer cells under hypoxia based on RNA sequencing. BMC Genom Data 2022;23:38. [PMID: 35590240 DOI: 10.1186/s12863-022-01055-9] [Reference Citation Analysis]
57 Amod A, Pahal S, Choudhary P, Gupta A, Singh S. Network pharmacological evaluation of strigolactones efficacy as potential inhibitors against therapeutic targets of hepatocellular carcinoma. Biotechnol Lett 2022;44:879-900. [PMID: 35672528 DOI: 10.1007/s10529-022-03266-7] [Reference Citation Analysis]
58 Deng LJ, Lei YH, Quan JY, Li BJ, Zhang DM, Tian HY, Chen Y, Zhang EX, Chen L, Ye WC, Ning WM, Yu LZ, Liu JS. 1β-OH-arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway. J Ethnopharmacol 2021;266:113443. [PMID: 33022344 DOI: 10.1016/j.jep.2020.113443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Jeng KS, Lu SJ, Wang CH, Chang CF. Liver Fibrosis and Inflammation under the Control of ERK2. Int J Mol Sci 2020;21:E3796. [PMID: 32471201 DOI: 10.3390/ijms21113796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Kamioka H, Edaki K, Kasahara H, Tomono T, Yano K, Ogihara T. Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells. J Pharm Pharmacol 2021:rgab051. [PMID: 34313784 DOI: 10.1093/jpp/rgab051] [Reference Citation Analysis]
61 Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, Lai L, Hazirah SN, Lim TKH, Goh BKP, Chung A, Lo RHG, Ng D, Filarca RLF, Albani S, Chow PKH. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019;68:335-46. [PMID: 29440463 DOI: 10.1136/gutjnl-2017-315485] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 24.0] [Reference Citation Analysis]
62 Roy S, Trautwein C, Luedde T, Roderburg C. A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases. Front Pharmacol 2018;9:805. [PMID: 30158867 DOI: 10.3389/fphar.2018.00805] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
63 Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumor Biol 2015;36:7439-47. [DOI: 10.1007/s13277-015-3430-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
64 Chaoul N, Mancarella S, Lupo L, Giannelli G, Dituri F. Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E627. [PMID: 32182707 DOI: 10.3390/cancers12030627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
65 Zhang B, Dong S, Li Z, Lu L, Zhang S, Chen X, Cen X, Wu Y. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin. J Transl Med 2015;13:349. [PMID: 26541651 DOI: 10.1186/s12967-015-0721-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
66 Zhou S, Jiang L, Sun M. Recurrent hypoglycemic coma as the initial and single clinical manifestation of advanced hepatocellular carcinoma. J Gastrointest Cancer. 2015;46:64-67. [PMID: 25407746 DOI: 10.1007/s12029-014-9670-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Tan W, He J, Deng J, Yang X, Cui L, Ran R, Du G, Jiang X. Small molecule metabolite biomarkers for hepatocellular carcinoma with bile duct tumor thrombus diagnosis. Sci Rep 2018;8:3309. [PMID: 29459779 DOI: 10.1038/s41598-018-21595-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
68 Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, Wang XW. Inhibition of wnt/β-catenin Signaling in Hepatocellular Carcinoma by an Antipsychotic Drug Pimozide. Int J Biol Sci 2016;12:768-75. [PMID: 27313491 DOI: 10.7150/ijbs.14718] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
69 Li Y, Shimizu S, Mizumoto M, Iizumi T, Numajiri H, Makishima H, Li G, Sakurai H. Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation. Cureus. [DOI: 10.7759/cureus.25744] [Reference Citation Analysis]
70 Song Y, Wang S, Cheng X. LINC01006 regulates the proliferation, migration and invasion of hepatocellular carcinoma cells through regulating miR-433-3p/CBX3 axis. Ann Hepatol 2021;25:100343. [PMID: 33781916 DOI: 10.1016/j.aohep.2021.100343] [Reference Citation Analysis]
71 Tan KW, Chacko AM, Chew V. PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:51. [PMID: 31463410 DOI: 10.21037/tgh.2019.06.08] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
72 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Karaman B, Battal B, Sari S, Verim S. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(47): 18059-18060 [PMID: 25548509 DOI: 10.3748/wjg.v20.i47.18059] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
74 Pham DC, Nguyen HC, Nguyen TL, Ho HL, Trinh TK, Riyaphan J, Weng CF. Optimization of Ultrasound-Assisted Extraction of Flavonoids from Celastrus hindsii Leaves Using Response Surface Methodology and Evaluation of Their Antioxidant and Antitumor Activities. Biomed Res Int 2020;2020:3497107. [PMID: 32337241 DOI: 10.1155/2020/3497107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Huang Y, Hu L, Huang S, Xu W, Wan J, Wang D, Zheng G, Xia Z. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. Int J Nanomedicine 2018;13:8309-23. [PMID: 30584302 DOI: 10.2147/IJN.S184379] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
76 Wu HC, Cheng MJ, Yen CH, Chen YA, Chen YS, Chen IS, Chang HS. Chemical Constituents with GNMT-Promoter-Enhancing and NRF2-Reduction Activities from Taiwan Agarwood Excoecaria formosana. Molecules 2020;25:E1746. [PMID: 32290267 DOI: 10.3390/molecules25071746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res 2017;2:129-36. [PMID: 30159431 DOI: 10.1016/j.ncrna.2017.11.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
78 Lin TA, Lin JS, Wagner T, Pham N. Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions. J Gastrointest Oncol 2018;9:858-70. [PMID: 30505586 DOI: 10.21037/jgo.2018.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Tak H, Kang H, Ji E, Hong Y, Kim W, Lee EK. Potential use of TIA-1, MFF, microRNA-200a-3p, and microRNA-27 as a novel marker for hepatocellular carcinoma. Biochem Biophys Res Commun 2018;497:1117-22. [PMID: 29496454 DOI: 10.1016/j.bbrc.2018.02.189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
80 Zhou Y, Sun K, Ma Y, Yang H, Zhang Y, Kong X, Wei L. Autophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells. Sci Rep 2014;4:5382. [PMID: 24947039 DOI: 10.1038/srep05382] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
81 Zhang S, Cheng ZM, Yu JL, Lu K, Xu SJ, Lu Y, Liu T, Xia BJ, Huang Z, Zhao XY, He W, Li JX, Cao W, Huang Y, Wang L, Zeng Z, Zou X, Liu R, Zhang YS, Wu XP, Jiang TP, Zhou S. Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride production. Cancer Med 2021;10:6795-806. [PMID: 34427987 DOI: 10.1002/cam4.4209] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Juarez-Flores A, José MV. Multivariate Entropy Characterizes the Gene Expression and Protein-Protein Networks in Four Types of Cancer. Entropy (Basel) 2018;20:E154. [PMID: 33265245 DOI: 10.3390/e20030154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Yao X, Yan D, Zeng H, Liu D, Li H. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. J Surg Oncol 2016;113:672-7. [PMID: 26989044 DOI: 10.1002/jso.24215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
84 Song H, Liu Y, Li X, Chen S, Xie R, Chen D, Gao H, Wang G, Cai B, Yang X. Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3-mediated E2F1 activation. Clin Transl Med 2020;10:e220. [PMID: 33252856 DOI: 10.1002/ctm2.220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
85 Atiya A, Sinha BN, Ranjan Lal U. New chemical constituents from the Piper betle Linn. (Piperaceae). Natural Product Research 2018;32:1080-7. [DOI: 10.1080/14786419.2017.1380018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
86 Lin Y, Pan XB. Differences in Survival Between First-Line Radiofrequency Ablation versus Surgery for Early-Stage Hepatocellular Carcinoma: A Population Study Using the Surveillance, Epidemiology, and End Results Database. Med Sci Monit 2020;26:e921782. [PMID: 32461542 DOI: 10.12659/MSM.921782] [Reference Citation Analysis]
87 Ding J, Tang B, Liu X, Bai X, Wang Y, Li S, Li J, Liu M, Wang X. Excretory-secretory product of Trichinella spiralis inhibits tumor cell growth by regulating the immune response and inducing apoptosis. Acta Trop 2022;225:106172. [PMID: 34627760 DOI: 10.1016/j.actatropica.2021.106172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Pan H, Wang Z, Jiang L, Sui X, You L, Shou J, Jing Z, Xie J, Ge W, Cai X. Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci Rep. 2014;4:6683. [PMID: 25327881 DOI: 10.1038/srep06683] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
89 Ting CT, Cheng YY, Tsai TH. Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ACS Omega 2021;6:3060-7. [PMID: 33553923 DOI: 10.1021/acsomega.0c05461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Chen J, Huang S, Li I, Lin K, Tsay S. Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma. Support Care Cancer 2019;27:4665-74. [DOI: 10.1007/s00520-019-04776-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
91 Hu K, Li NF, Li JR, Chen ZG, Wang JH, Sheng LQ. Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR-3619-5p/SOX9. Hepatol Res 2021. [PMID: 34233088 DOI: 10.1111/hepr.13692] [Reference Citation Analysis]
92 Del Carpio E, Hernández L, Ciangherotti C, Villalobos Coa V, Jiménez L, Lubes V, Lubes G. Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications. Coord Chem Rev 2018;372:117-40. [PMID: 32226092 DOI: 10.1016/j.ccr.2018.06.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 9.3] [Reference Citation Analysis]
93 Kozeniecki M, Ludke R, Kerner J, Patterson B. Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation.Nutr Clin Pract. 2020;35:50-62. [PMID: 31840874 DOI: 10.1002/ncp.10451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
94 Lin GH, Shih YL. Paraplegia following transarterial chemoembolisation for hepatocellular carcinoma: a case report. Acta Chir Belg 2021;121:437-40. [PMID: 32031042 DOI: 10.1080/00015458.2020.1726097] [Reference Citation Analysis]
95 Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Int J Mol Sci 2016;17:E1618. [PMID: 27669229 DOI: 10.3390/ijms17101618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
96 He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chin J Cancer 2017;36:59. [PMID: 28728568 DOI: 10.1186/s40880-017-0227-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
97 Wang C, Zhou X, Xu H, Shi X, Zhao J, Yang M, Zhang L, Jin X, Hu Y, Li X, Xiao X, Liao M. Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway. J Cancer 2018;9:4150-5. [PMID: 30519314 DOI: 10.7150/jca.26948] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
98 Bhatt S, Kanoujia J, Dhar AK, Singh RK, Rajangam J. Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma. CCTR 2021;17:148-58. [DOI: 10.2174/1573394716999200818103724] [Reference Citation Analysis]
99 Dos Santos DC, Rafique J, Saba S, Almeida GM, Siminski T, Pádua C, Filho DW, Zamoner A, Braga AL, Pedrosa RC, Ourique F. Apoptosis oxidative damage-mediated and antiproliferative effect of selenylated imidazo[1,2-a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo. J Biochem Mol Toxicol 2021;35:e22663. [PMID: 33125183 DOI: 10.1002/jbt.22663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
100 Palakhachane S, Ketkaew Y, Chuaypen N, Sirirak J, Boonsombat J, Ruchirawat S, Tangkijvanich P, Suksamrarn A, Limpachayaporn P. Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines. Bioorg Chem 2021;112:104831. [PMID: 33831675 DOI: 10.1016/j.bioorg.2021.104831] [Reference Citation Analysis]
101 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Chacko S, Samanta S. "Hepatocellular carcinoma: A life-threatening disease". Biomed Pharmacother. 2016;84:1679-1688. [PMID: 27823920 DOI: 10.1016/j.biopha.2016.10.078] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
103 Wu G, Li Z, Wang Y, Ju X, Huang R. miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma. Biomed Res Int. 2018;2018:2863902. [PMID: 30627547 DOI: 10.1155/2018/2863902] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
104 Kazmierczak PM, Theisen D, Thierfelder KM, Sommer WH, Reiser MF, Notohamiprodjo M, Nikolaou K. Improved detection of hypervascular liver lesions with CAIPIRINHA-Dixon-TWIST-volume-interpolated breath-hold examination. Invest Radiol 2015;50:153-60. [PMID: 25478742 DOI: 10.1097/RLI.0000000000000118] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
105 Fu XH, Li M, Lou HB, Huang MS, Liu CL. Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma. Genet Res (Camb) 2016;98:e14. [PMID: 27834158 DOI: 10.1017/S0016672316000124] [Reference Citation Analysis]
106 Mkhwanazi NK, de Koning CB, van Otterlo WAL, Ariatti M, Singh M. PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor. Z Naturforsch C J Biosci 2017;72:293-301. [PMID: 28063265 DOI: 10.1515/znc-2016-0172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
107 Shin WJ, Zabel BA, Pachynski RK. Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention. Front Immunol 2018;9:2772. [PMID: 30555465 DOI: 10.3389/fimmu.2018.02772] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
108 Lai HH, Li CW, Hong CC, Sun HY, Chiu CF, Ou DL, Chen PS. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Mol Oncol 2019;13:928-45. [PMID: 30657254 DOI: 10.1002/1878-0261.12449] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
109 Samarakoon SR, Shanmuganathan C, Ediriweera MK, Piyathilaka P, Tennekoon KH, Thabrew I, Galhena P, De Silva ED. Anti-hepatocarcinogenic and Anti-oxidant Effects of Mangrove Plant Scyphiphora hydrophyllacea. Pharmacogn Mag 2017;13:S76-83. [PMID: 28479730 DOI: 10.4103/0973-1296.203989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
110 Boyle DA. Hepatocellular Carcinoma: Implications for Asia-Pacific Oncology Nurses. Asia Pac J Oncol Nurs 2017;4:98-103. [PMID: 28503639 DOI: 10.4103/2347-5625.204497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Filippi L, Di Costanzo GG, D’agostini A, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nuclear Medicine Communications 2018;39:845-52. [DOI: 10.1097/mnm.0000000000000879] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
112 Lu J, Wang J, Ling D. Surface Engineering of Nanoparticles for Targeted Delivery to Hepatocellular Carcinoma. Small 2018;14. [PMID: 29251419 DOI: 10.1002/smll.201702037] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
113 Zhang YH, Brehmer K, Svensson A, Herlin G, Stål P, Brismar TB. Variation in textural parameters of hepatic lesions during contrast medium injection. Acta Radiol 2021;62:1317-23. [PMID: 33108894 DOI: 10.1177/0284185120964904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zheng Y, Liu Y, Zhao S, Zheng Z, Shen C, An L, Yuan Y. Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. Cancer Manag Res 2018;10:6079-96. [PMID: 30538557 DOI: 10.2147/CMAR.S181396] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
115 Aglan HA, Ahmed HH, El-Toumy SA, Mahmoud NS. Gallic acid against hepatocellular carcinoma: An integrated scheme of the potential mechanisms of action from in vivo study. Tumour Biol 2017;39:1010428317699127. [PMID: 28618930 DOI: 10.1177/1010428317699127] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
116 Li X, Xu A, Li H, Zhang B, Cao B, Huang J. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1693-1701. [PMID: 29486282 DOI: 10.1016/j.bbadis.2018.02.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
117 Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R. 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med. 2015;Epub ahead of print. [PMID: 25698299 DOI: 10.1007/s11547-015-0514-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
118 Li Y, Li Y, Zou Z, Li Y, Xie H, Yang H. Yin Yang Gong Ji pill is an ancient formula with antitumor activity against hepatoma cells. Journal of Ethnopharmacology 2020;248:112267. [DOI: 10.1016/j.jep.2019.112267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Rahman M, Beg S, Alharbi KS, Alruwaili NK, Alotaibi NH, Alzarea AI, Almalki WH, Alenezi SK, Altowayan WM, Alshammari MS, Afzal M, Saleem S, Kumar V. Implications of Solid Lipid Nanoparticles of Ganoderic Acid for the Treatment and Management of Hepatocellular Carcinoma. J Pharm Innov 2021;16:359-70. [DOI: 10.1007/s12247-020-09450-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
121 Yue D, Sun X. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. Cell Death Dis 2018;9:935. [PMID: 30224718 DOI: 10.1038/s41419-018-0960-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
122 Fang Z, He L, Jia H, Huang Q, Chen D, Zhang Z. The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer. Iran J Basic Med Sci 2017;20:187-92. [PMID: 28293396 DOI: 10.22038/ijbms.2017.8246] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
123 Zhao Z, Song J, Zhang D, Wu F, Tu J, Ji J. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sci 2021;264:118642. [PMID: 33148422 DOI: 10.1016/j.lfs.2020.118642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Kutlu OC, Chan JA, Aloia TA, Chun YS, Kaseb AO, Passot G, Yamashita S, Vauthey JN, Conrad C. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer. 2017;123:1817-1827. [PMID: 28085184 DOI: 10.1002/cncr.30531] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
125 Paixão A, Silva R, Lopes N, Carvalho S, Carrola P, Presa ramos J. Isolated Intracardiac Metastasis: The First Sign of Hepatocellular Carcinoma. GE Port J Gastroenterol. [DOI: 10.1159/000519545] [Reference Citation Analysis]
126 Jia R, Xu H, Wang C, Su L, Jing J, Xu S, Zhou Y, Sun W, Song J, Chen X, Chen H. NIR-II emissive AIEgen photosensitizers enable ultrasensitive imaging-guided surgery and phototherapy to fully inhibit orthotopic hepatic tumors. J Nanobiotechnology 2021;19:419. [PMID: 34903233 DOI: 10.1186/s12951-021-01168-w] [Reference Citation Analysis]
127 Hernandez R, Sun H, England CG, Valdovinos HF, Ehlerding EB, Barnhart TE, Yang Y, Cai W. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. Theranostics 2016;6:1918-33. [PMID: 27570560 DOI: 10.7150/thno.15568] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
128 Shoshan MS, Vonderach T, Hattendorf B, Wennemers H. Peptide‐Coated Platinum Nanoparticles with Selective Toxicity against Liver Cancer Cells. Angew Chem Int Ed 2019;58:4901-5. [DOI: 10.1002/anie.201813149] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
129 Liu HY, Qian HH, Zhang XF, Li J, Yang X, Sun B, Ma JY, Chen L, Yin ZF. Improved method increases sensitivity for circulating hepatocellular carcinoma cells. World J Gastroenterol 2015; 21(10): 2918-2925 [PMID: 25780289 DOI: 10.3748/wjg.v21.i10.2918] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
130 Rana MM, Melancon MP. Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope. Biomimetics (Basel) 2022;7:77. [PMID: 35735593 DOI: 10.3390/biomimetics7020077] [Reference Citation Analysis]
131 Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. J Immunol 2019;203:198-207. [PMID: 31142602 DOI: 10.4049/jimmunol.1800033] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
132 Aly A, Lingohr-Smith M, Lin J, Seal B. Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. Hepat Oncol 2021;8:HEP37. [PMID: 34408847 DOI: 10.2217/hep-2021-0001] [Reference Citation Analysis]
133 Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep 2015;14:128-38. [PMID: 26328266 DOI: 10.1007/s11901-015-0261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
134 Aliyu-amoo H, Isa HI, Njoya EM, Mcgaw LJ. Antiproliferative effect of extracts and fractions of the root of Terminalia avicennioides (Combretaceae) Guill and Perr. on HepG2 and Vero cell lines. Clin Phytosci 2021;7. [DOI: 10.1186/s40816-021-00307-y] [Reference Citation Analysis]
135 Amin MN, Siddiqui SA, Ibrahim M, Hakim ML, Ahammed MS, Kabir A, Sultana F. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med 2020;8:2050312120965752. [PMID: 33194199 DOI: 10.1177/2050312120965752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
136 Chen X, Zhang S, Wang Z, Wang F, Cao X, Wu Q, Zhao C, Ma H, Ye F, Wang H, Fang Z. Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway. J Exp Clin Cancer Res 2018;37:128. [PMID: 29954442 DOI: 10.1186/s13046-018-0787-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
137 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]
139 Zhu K, Huang W, Wang W, Liao L, Li S, Yang S, Xu J, Li L, Meng M, Xie Y, He S, Tang W, Zhou H, Liang L, Gao H, Zhao Y, Hou Z, Tan J, Li R. Up-regulation of S100A4 expression by HBx protein promotes proliferation of hepatocellular carcinoma cells and its correlation with clinical survival. Gene 2020;749:144679. [PMID: 32330536 DOI: 10.1016/j.gene.2020.144679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
140 Yang X, Sun L, Wang L, Yao B, Mo H, Yang W. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomedicine & Pharmacotherapy 2019;118:109386. [DOI: 10.1016/j.biopha.2019.109386] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
141 Nagpal P, Bhalala M, Vidholia A, Sao R, Sharma N, Mehta D, McCabe S, Bodin R. Abdominal Skin Rash After TACE Due to Non-Target Embolization of Hepatic Falciform Artery. ACG Case Rep J 2016;3:217-20. [PMID: 27144210 DOI: 10.14309/crj.2016.55] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
142 Yu JJ, Shen F, Chen TH, Liang L, Han J, Xing H, Zhou YH, Wang H, Gu WM, Lau WY, Yang T. Multicentre study of the prognostic impact of preoperative bodyweight on long-term prognosis of hepatocellular carcinoma. Br J Surg 2019;106:276-85. [PMID: 30199100 DOI: 10.1002/bjs.10981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
143 Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL, Hu H. Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review. Front Public Health 2022;10:801981. [PMID: 35530735 DOI: 10.3389/fpubh.2022.801981] [Reference Citation Analysis]
144 Wang TH, Yeh CT, Ho JY, Ng KF, Chen TC. OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma. Mol Carcinog. 2016;55:366-375. [PMID: 25663355 DOI: 10.1002/mc.22286] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
145 Sharma N, Biswas S, Al-Dayan N, Alhegaili AS, Sarwat M. Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants (Basel) 2021;10:1419. [PMID: 34573051 DOI: 10.3390/antiox10091419] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
146 Krishnan V, Loganathan C, Thayumanavan P. Green synthesized selenium nanoparticle as carrier and potent delivering agent of s-allyl glutathione: Anticancer effect against hepatocarcinoma cell line (HepG2) through induction of cell cycle arrest and apoptosis. Journal of Drug Delivery Science and Technology 2019;53:101207. [DOI: 10.1016/j.jddst.2019.101207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
147 Mabrouk AA, Eltablawy NA, El-allawy RM, Abdel Maksoud H, Elsenosi YA. The ameliorating effect of Terminalia muelleri extract on oxidative stress–related factors in induced hepatocellular carcinoma rat model. Gene Reports 2022;26:101482. [DOI: 10.1016/j.genrep.2021.101482] [Reference Citation Analysis]
148 Miranda MLP, Furtado KS, de Oliveira Andrade F, Heidor R, da Cruz RS, Nogueira MS, de Castro IA, Purgatto E, Barbisan LF, Moreno FS. β-ionone inhibits nonalcoholic fatty liver disease and its association with hepatocarcinogenesis in male Wistar rats. Chem Biol Interact 2019;308:377-84. [PMID: 31150631 DOI: 10.1016/j.cbi.2019.05.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Bhangoo RS, Mullikin TC, Ashman JB, Cheng TW, Golafshar MA, DeWees TA, Johnson JE, Shiraishi S, Liu W, Hu Y, Merrell KW, Haddock MG, Krishnan S, Rule WG, Sio TT, Hallemeier CL. Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. Adv Radiat Oncol 2021;6:100675. [PMID: 34409199 DOI: 10.1016/j.adro.2021.100675] [Reference Citation Analysis]
151 Chen Z, Yuan T, Yan F, Ye S, Xie Q, Zhang B, Lin N, He Q, Yang B, Zhu H. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. BMC Cancer 2022;22:425. [PMID: 35440025 DOI: 10.1186/s12885-022-09520-5] [Reference Citation Analysis]
152 D'Emic N, Engelman A, Molitoris J, Hanlon A, Sharma NK, Moeslein FM, Chuong MD. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy. J Gastrointest Oncol. 2016;7:269-277. [PMID: 27034796 DOI: 10.3978/j.issn.2078-6891.2015.108] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
153 Luu S, Hsu C, Silberfein EJ. Demographic and Clinicopathologic Factors of Patients With Hepatocellular Carcinoma in a Safety Net Hospital. J Surg Res 2020;256:374-80. [PMID: 32739621 DOI: 10.1016/j.jss.2020.06.046] [Reference Citation Analysis]
154 Raman V, Van Dessel N, Hall CL, Wetherby VE, Whitney SA, Kolewe EL, Bloom SMK, Sharma A, Hardy JA, Bollen M, Van Eynde A, Forbes NS. Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases. Nat Commun 2021;12:6116. [PMID: 34675204 DOI: 10.1038/s41467-021-26367-9] [Reference Citation Analysis]
155 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
156 Zhang J, Li J, Shi Z, Yang Y, Xie X, Lee SM, Wang Y, Leong KW, Chen M. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Acta Biomater 2017;58:349-64. [PMID: 28455219 DOI: 10.1016/j.actbio.2017.04.029] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 22.4] [Reference Citation Analysis]
157 Dey D, Banerjee M. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol 2016;4:248-57. [PMID: 27777893 DOI: 10.14218/JCTH.2016.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
158 Luo X, Zhou N, Wang L, Zeng Q, Tang H. Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53. Can J Gastroenterol Hepatol 2019;2019:1389653. [PMID: 31871924 DOI: 10.1155/2019/1389653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
159 Mandal D, Shaw TK, Dey G, Pal MM, Mukherjee B, Bandyopadhyay AK, Mandal M. Preferential hepatic uptake of paclitaxel-loaded poly-(d-l-lactide-co-glycolide) nanoparticles — A possibility for hepatic drug targeting: Pharmacokinetics and biodistribution. International Journal of Biological Macromolecules 2018;112:818-30. [DOI: 10.1016/j.ijbiomac.2018.02.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
160 Wang W, Zhang C, Yu Q, Zheng X, Yin C, Yan X, Liu G, Song Z. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients. BMC Gastroenterol 2021;21:68. [PMID: 33579192 DOI: 10.1186/s12876-021-01638-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
162 Kanno S, Kurauchi K, Tomizawa A, Yomogida S, Ishikawa M. Pifithrin-alpha has a p53-independent cytoprotective effect on docosahexaenoic acid-induced cytotoxicity in human hepatocellular carcinoma HepG2 cells. Toxicology Letters 2015;232:393-402. [DOI: 10.1016/j.toxlet.2014.11.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
163 Xie B, He X, Guo G, Zhang X, Li J, Liu J, Lin Y. High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. Biochem Biophys Res Commun 2020;521:232-7. [PMID: 31653348 DOI: 10.1016/j.bbrc.2019.10.114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
164 Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplant 2017;26:429-38. [PMID: 28195035 DOI: 10.3727/096368916X694382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
165 Wang TH, Wu CH, Yeh CT, Su SC, Hsia SM, Liang KH, Chen CC, Hsueh C, Chen CY. Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation. Oncotarget 2017;8:82280-93. [PMID: 29137263 DOI: 10.18632/oncotarget.19316] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
166 Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Can J Gastroenterol Hepatol 2021;2021:8837811. [PMID: 33728291 DOI: 10.1155/2021/8837811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
167 Shahzadi I, Ali Z, Bukhari S, Narula AS, Mirza B, Mohammadinejad R. Possible applications of salvianolic acid B against different cancers. Exploration of Targeted Anti-tumor Therapy 2020;1:218-38. [DOI: 10.37349/etat.2020.00014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
168 Varghese J, Kedarisetty CK, Venkataraman J, Srinivasan V, Deepashree T, Uthappa MC, Ilankumaran K, Govil S, Srinivas Reddy M, Rela M. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. Annals of Hepatology 2017;16:247-54. [DOI: 10.5604/16652681.1231585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
169 Jiang J, Chen Y, Dong T, Yue M, Zhang Y, An T, Zhang J, Liu P, Yang X. Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway. Oncol Lett 2019;17:4505-13. [PMID: 30944640 DOI: 10.3892/ol.2019.10123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
170 Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology. 2019;156:1862-1876.e9. [PMID: 30711630 DOI: 10.1053/j.gastro.2019.01.251] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
171 Abdelrahim M, Victor D, Esmail A, Kodali S, Graviss EA, Nguyen DT, Moore LW, Saharia A, McMillan R, Fong JN, Uosef A, Elshawwaf M, Heyne K, Ghobrial RM. Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience. Cancers (Basel) 2022;14:650. [PMID: 35158918 DOI: 10.3390/cancers14030650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
172 Zhao Y, Wu H, Xing X, Ma Y, Ji S, Xu X, Zhao X, Wang S, Jiang W, Fang C, Zhang L, Yan F, Wang X. CD13 Induces Autophagy to Promote Hepatocellular Carcinoma Cell Chemoresistance Through the P38/Hsp27/CREB/ATG7 Pathway. J Pharmacol Exp Ther 2020;374:512-20. [PMID: 32571958 DOI: 10.1124/jpet.120.265637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
173 Asgharzadeh F, Jafarzadeh-esfehani R, Hassanian SM, Ferns GA, Avan A, Khazaei M. Renin-angiotensin System Inhibitors and Development of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. CPD 2020;26:5079-85. [DOI: 10.2174/1381612826666200713165018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Xie J, Zhang A, Wang X. Metabolomic applications in hepatocellular carcinoma: toward the exploration of therapeutics and diagnosis through small molecules. RSC Adv 2017;7:17217-26. [DOI: 10.1039/c7ra00698e] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
175 Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. J Cancer 2019;10:1189-96. [PMID: 30854128 DOI: 10.7150/jca.28994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
176 Hu Z, Yang A, Su G, Zhao Y, Wang Y, Chai X, Tu P. Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV. Sci Rep 2016;6:31298. [PMID: 27503760 DOI: 10.1038/srep31298] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
177 Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control 2021;32:317-25. [PMID: 33394207 DOI: 10.1007/s10552-020-01386-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Wei L, Owen D, Rosen B, Guo X, Cuneo K, Lawrence TS, Ten Haken R, El Naqa I. A deep survival interpretable radiomics model of hepatocellular carcinoma patients. Phys Med 2021;82:295-305. [PMID: 33714190 DOI: 10.1016/j.ejmp.2021.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68 [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
180 Zhang W, Liu K, Liu S, Ji B, Wang Y, Liu Y. MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. Tumor Biol 2015;36:9779-88. [DOI: 10.1007/s13277-015-3749-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
181 Chen YS, Sun ZW, Meng CC, Tang JZ, Li XY, Wang JF, Liu L, Zhang LJ. Molecular pathogenesis and molecular targeted agents for primary liver cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(6): 914-924 [DOI: 10.11569/wcjd.v23.i6.914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Liu Y, Liu R, Wang P, Li S, Shen H. Percutaneous implantation of 125iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0657-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
183 Shen Q, Xia Y, Yang L, Wang B, Peng J, Tang M. Midazolam Suppresses Hepatocellular Carcinoma Cell Metastasis and Enhances Apoptosis by Elevating miR-217. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/2813521] [Reference Citation Analysis]
184 Seydi E, Rahimpour Z, Salimi A, Pourahmad J. Selective toxicity of chrysin on mitochondria isolated from liver of a HCC rat model. Bioorg Med Chem. 2019;27:115163. [PMID: 31708277 DOI: 10.1016/j.bmc.2019.115163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
185 Healy K, Pavesi A, Parrot T, Sobkowiak MJ, Reinsbach SE, Davanian H, Tan AT, Aleman S, Sandberg JK, Bertoletti A, Sällberg Chen M. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Rep 2021;3:100318. [PMID: 34377970 DOI: 10.1016/j.jhepr.2021.100318] [Reference Citation Analysis]
186 He L, Cai X, Cheng S, Zhou H, Zhang Z, Ren J, Ren F, Yang Q, Tao N, Chen J. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2019;17:5030-8. [PMID: 31186714 DOI: 10.3892/ol.2019.10174] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Mihcin S, Gagliardo C, Toia P, Dennison A, Strehlow J, Melzer A. MR-guided focused ultrasound application for moving target tumor ablation in abdominal area: coil selection. Acta Radiol 2021;62:3-11. [PMID: 32276552 DOI: 10.1177/0284185120914059] [Reference Citation Analysis]
188 Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int 2021;21:208. [PMID: 33849569 DOI: 10.1186/s12935-021-01924-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Liu W, Huai R, Zhang Y, Rao S, Xiong L, Ding R, Mao C, Zhao W, Hao T, Huang Q, Guo Z. Down-regulation expression of TGFB2-AS1 inhibits the proliferation, migration, invasion and induces apoptosis in HepG2 cells. Genes Genomics 2019;41:951-9. [PMID: 31066006 DOI: 10.1007/s13258-019-00826-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Hung YH, Lin YC, Lin YT, Shih GW, Liao JW, Chen KS, Liu HM, Chen YW, Chuang YJ, Yang CM, Peir JJ, Yang CH, Chou FI. Suitability of boric acid as a boron drug for boron neutron capture therapy for hepatoma. Appl Radiat Isot 2020;164:109254. [PMID: 32554126 DOI: 10.1016/j.apradiso.2020.109254] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Wittmann C, Sivchenko AS, Bacher F, Tong KKH, Guru N, Wilson T, Gonzales J, Rauch H, Kossatz S, Reiner T, Babak MV, Arion VB. Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes. Inorg Chem 2022;61:1456-70. [PMID: 34995063 DOI: 10.1021/acs.inorgchem.1c03154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
192 Maji M, Bhattacharya I, Acharya S, Chakraborty MP, Gupta A, Mukherjee A. Hypoxia Active Platinum(IV) Prodrugs of Orotic Acid Selective to Liver Cancer Cells. Inorg Chem 2021;60:4342-6. [PMID: 33711231 DOI: 10.1021/acs.inorgchem.0c03803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
193 Helmy SA, El-mesery M, El-karef A, Eissa LA, El Gayar AM. Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model. Life Sciences 2019;233:116673. [DOI: 10.1016/j.lfs.2019.116673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
194 Ezhuthupurakkal PB, Ariraman S, Arumugam S, Subramaniyan N, Muthuvel SK, Kumpati P, Rajamani B, Chinnasamy T. Anticancer potential of ZnO nanoparticle-ferulic acid conjugate on Huh-7 and HepG2 cells and diethyl nitrosamine induced hepatocellular cancer on Wistar albino rat. Nanomedicine 2018;14:415-28. [PMID: 29166623 DOI: 10.1016/j.nano.2017.11.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
195 Wang H, Ellipilli S, Lee WJ, Li X, Vieweger M, Ho YS, Guo P. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. J Control Release 2021;330:173-84. [PMID: 33316298 DOI: 10.1016/j.jconrel.2020.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
196 Aydin Y, Koksal AR, Thevenot P, Chava S, Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. JHC 2021;Volume 8:1579-96. [DOI: 10.2147/jhc.s327339] [Reference Citation Analysis]
197 Ruan DY, Lin ZX, Li Y, Jiang N, Li X, Wu DH, Wang TT, Chen J, Lin Q, Wu XY. Poor oncologic outcomes of hepatocellular carcinoma patients with intra-abdominal infection after hepatectomy. World J Gastroenterol 2015; 21(18): 5598-5606 [PMID: 25987785 DOI: 10.3748/wjg.v21.i18.5598] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
198 Han XJ, Su HY, Shao HB, Xu K. Prognostic factors of spontaneously ruptured hepatocellular carcinoma. World J Gastroenterol 2015; 21(24): 7488-7494 [PMID: 26139994 DOI: 10.3748/wjg.v21.i24.7488] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
199 Dou C, Xu Q, Liu J, Wang Y, Zhou Z, Yao W, Jiang K, Cheng J, Zhang C, Tu K. SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production. J Exp Clin Cancer Res 2019;38:70. [PMID: 30755243 DOI: 10.1186/s13046-019-1067-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
200 Maurya AK, Vinayak M. Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep 2015;42:1419-29. [DOI: 10.1007/s11033-015-3921-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
201 Yang X, Yao B, Niu Y, Chen T, Mo H, Wang L, Guo C, Yao D. Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122–5p/CTNND2 axis. Biochemical and Biophysical Research Communications 2019;518:239-45. [DOI: 10.1016/j.bbrc.2019.08.039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
202 Fairman J, Liu KH, Menne S. Prevention of liver tumor formation in woodchucks with established hepatocellular carcinoma by treatment with cationic liposome-DNA complexes. BMC Cancer. 2017;17:172. [PMID: 28264666 DOI: 10.1186/s12885-017-3163-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
203 Becker-assmann J, Fard-aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, von Hahn T, Oldhafer KJ. Diagnostische und prognostische Bedeutung des α-Feto-Proteins beim hepatozellulären Karzinom. Chirurg 2020;91:769-77. [DOI: 10.1007/s00104-020-01118-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
204 Wang HL, Zhang JP, Li DY, Han LL, Li JS. Clinical significance of BANCR expression in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(2): 196-202 [DOI: 10.11569/wcjd.v24.i2.196] [Reference Citation Analysis]
205 Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA, Yang YJ. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis 2020;11:676. [PMID: 32826865 DOI: 10.1038/s41419-020-02853-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
206 Chen CC, Chen CY, Wang SH, Yeh CT, Su SC, Ueng SH, Chuang WY, Hsueh C, Wang TH. Melatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair. Cancers (Basel) 2018;10:E320. [PMID: 30201872 DOI: 10.3390/cancers10090320] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
207 Nevzorova YA, Grossmann J, Trautwein C. Anti-tumorigenic and anti-angiogenic effects of natural conifer Abies sibirica terpenoids in vivo and in vitro. Biomedicine & Pharmacotherapy 2017;89:386-95. [DOI: 10.1016/j.biopha.2017.02.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
208 Buskaran K, Hussein MZ, Moklas MAM, Masarudin MJ, Fakurazi S. Graphene Oxide Loaded with Protocatechuic Acid and Chlorogenic Acid Dual Drug Nanodelivery System for Human Hepatocellular Carcinoma Therapeutic Application. Int J Mol Sci 2021;22:5786. [PMID: 34071389 DOI: 10.3390/ijms22115786] [Reference Citation Analysis]
209 Zhang Z, He CZ, Qin YQ, Liao JJ, Huang ST, Mo S, Li HM, Lin JY. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines. Aging (Albany NY) 2020;12:24255-69. [PMID: 33234725 DOI: 10.18632/aging.104195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Li M, Wang J, Song J, Shen F, Song L, Ni X, Suo T, Liu H, Zhong M, Liu H. Preoperative ICG Test to Predict Posthepatectomy Liver Failure and Postoperative Outcomes in Hilar Cholangiocarcinoma. Biomed Res Int 2021;2021:8298737. [PMID: 33681380 DOI: 10.1155/2021/8298737] [Reference Citation Analysis]
211 Helal M, Yan C, Gong Z. Stimulation of hepatocarcinogenesis by activated cholangiocytes via Il17a/f1 pathway in kras transgenic zebrafish model. Sci Rep 2021;11:1372. [PMID: 33446803 DOI: 10.1038/s41598-020-80621-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
212 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
213 Sapisochin G, Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol 2014; 6(11): 766-775 [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
214 Wang TH, Hsueh C, Chen CC, Li WS, Yeh CT, Lian JH, Chang JL, Chen CY. Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction. Int J Mol Sci 2018;19:E2687. [PMID: 30201903 DOI: 10.3390/ijms19092687] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
215 Xu L, Wang T, Meng WY, Wei J, Ma JL, Shi M, Wang YG. Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression. Oncol Rep 2015;33:1057-63. [PMID: 25522777 DOI: 10.3892/or.2014.3680] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
216 Li H, Wei N, Ma Y, Wang X, Zhang Z, Zheng S, Yu X, Liu S, He L. Integrative module analysis of HCC gene expression landscapes. Exp Ther Med 2020;19:1779-88. [PMID: 32104233 DOI: 10.3892/etm.2020.8437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Bigot A, Soulez G, Martel S. A prototype of injector to control and to detect the release of magnetic beads within the constraints of multibifurcation magnetic resonance navigation procedures. Magn Reson Med 2017;77:444-52. [PMID: 26898722 DOI: 10.1002/mrm.26109] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
218 Wasmer MH, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol 2016;7:682. [PMID: 28119694 DOI: 10.3389/fimmu.2016.00682] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
219 Chen S, Chen H, Gao S, Qiu S, Zhou H, Yu M, Tu J. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res. 2017;47:312-320. [PMID: 27152955 DOI: 10.1111/hepr.12739] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
220 Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey J, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers 2022;14:1901. [DOI: 10.3390/cancers14081901] [Reference Citation Analysis]
221 Zhang CZ, Fang EF, Zhang HT, Liu LL, Yun JP. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest New Drugs 2015;33:1-11. [PMID: 25200916 DOI: 10.1007/s10637-014-0156-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
222 Herrero A, Knetemann E, Mannaerts I. Review: Challenges of In Vitro CAF Modelling in Liver Cancers. Cancers (Basel) 2021;13:5914. [PMID: 34885024 DOI: 10.3390/cancers13235914] [Reference Citation Analysis]
223 Liu J, Li X, Huang J, Liu Y. Matrix Metalloproteinase 2 Knockdown Suppresses the Proliferation of HepG2 and Huh7 Cells and Enhances the Cisplatin Effect. Open Med (Wars) 2019;14:384-91. [PMID: 31157304 DOI: 10.1515/med-2019-0039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
224 Guerrero L, Sangro B, Ambao V, Granero JI, Ramos-Fernández A, Paradela A, Corrales FJ. Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease. J Physiol Biochem 2021. [PMID: 34897580 DOI: 10.1007/s13105-021-00856-3] [Reference Citation Analysis]
225 Lin YJ, Ho CM. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review. Medicina (Kaunas) 2021;57:131. [PMID: 33540784 DOI: 10.3390/medicina57020131] [Reference Citation Analysis]
226 Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14. [PMID: 31006227 DOI: 10.14366/usg.18060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
227 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
228 Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, Hwang M, Brock KK, Yeap BY, Wolfgang JA, Hong TS, Grassberger C. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. Int J Radiat Oncol Biol Phys 2020;107:986-95. [PMID: 32353390 DOI: 10.1016/j.ijrobp.2020.04.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
229 Hu C, Shen SQ, Cui ZH, Chen ZB, Li W. Effect of microRNA-1 on hepatocellular carcinoma tumor endothelial cells. World J Gastroenterol 2015; 21(19): 5884-5892 [PMID: 26019452 DOI: 10.3748/wjg.v21.i19.5884] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
230 Ingle PV, Samsudin SZ, Chan PQ, Ng MK, Heng LX, Yap SC, Chai AS, Wong AS. Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag. 2016;12:445-455. [PMID: 27042086 DOI: 10.2147/tcrm.s92377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
231 Granata V, Fusco R, Setola SV, Picone C, Vallone P, Belli A, Incollingo P, Albino V, Tatangelo F, Izzo F, Petrillo A. Microvascular invasion and grading in hepatocellular carcinoma: correlation with major and ancillary features according to LIRADS. Abdom Radiol (NY) 2019;44:2788-800. [PMID: 31089780 DOI: 10.1007/s00261-019-02056-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
232 Wang R, Hu X, Liu X, Bai L, Gu J, Li Q. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis. PLoS One 2021;16:e0249881. [PMID: 33861762 DOI: 10.1371/journal.pone.0249881] [Reference Citation Analysis]
233 Song Z, Zhang G, Yu Y, Li S. A Prognostic Autophagy-Related Gene Pair Signature and Small-Molecule Drugs for Hepatocellular Carcinoma. Front Genet 2021;12:689801. [PMID: 34497633 DOI: 10.3389/fgene.2021.689801] [Reference Citation Analysis]
234 Pu J, Wang J, Xu Z, Lu Y, Wu X, Wu Y, Shao Z, Tang Q, Wei H. miR-632 Functions as Oncogene in Hepatocellular Carcinoma via Targeting MYCT1. Hum Gene Ther Clin Dev 2019;30:67-73. [PMID: 30982352 DOI: 10.1089/humc.2019.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
235 Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspectives. Exp Mol Med 2017;49:e359. [PMID: 28729640 DOI: 10.1038/emm.2017.85] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 10.6] [Reference Citation Analysis]
236 Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett 2017;13:984-92. [PMID: 28356989 DOI: 10.3892/ol.2016.5525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
237 Kronenfeld JP, Goel N. ASO Author Reflections: Access to Care and Screening Inequities for Patients At Risk for Hepatocellular Carcinoma. Ann Surg Oncol 2021;28:1937-8. [PMID: 32974697 DOI: 10.1245/s10434-020-09172-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
238 Shih Y, Peng C, Weng M, Chiang P, Luo T, Lin X. Evaluation Efficacy of Rhenium-188-Loaded Micro-particles for Radiotherapy in a Mouse Model of Hepatocellular Carcinoma. Mol Pharmaceutics 2019;16:1083-91. [DOI: 10.1021/acs.molpharmaceut.8b01083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
239 Feng Y, Wei G, Zhang L, Zhou H, Wang W, Guo P, Cheng C, Ji L, Cai Q, Feng Y, Tu H. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis. Bioengineered 2021;12:8217-32. [PMID: 34596006 DOI: 10.1080/21655979.2021.1982272] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Singh MK, Das BK, Choudhary S, Gupta D, Patil UK. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed Pharmacother 2018;106:991-1002. [PMID: 30119271 DOI: 10.1016/j.biopha.2018.06.095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
241 Zhang J, Yang G, Li Q, Xie F. Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma. Oncol Lett 2021;21:92. [PMID: 33376525 DOI: 10.3892/ol.2020.12353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Kuan A, Khoo L, Yang SS, Chia HY, Lee JSS. Retiform Purpura as a Complication of Microsphere Emboli Following Transarterial Chemoembolization for Primary Hepatocellular Carcinoma: A Case Report and Literature Review. The American Journal of Dermatopathology 2020;42:e108-10. [DOI: 10.1097/dad.0000000000001586] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
243 Tang JC, Feng YL, Liang X, Cai XJ. Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges. Chin Med J (Engl). 2016;129:456-463. [PMID: 26879020 DOI: 10.4103/0366-6999.176069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
244 Léveillé M, Estall JL. Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 2019;9:E233. [PMID: 31623280 DOI: 10.3390/metabo9100233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
245 Joliat GR, Allemann P, Labgaa I, Demartines N, Halkic N. Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402:737-744. [PMID: 28497194 DOI: 10.1007/s00423-017-1582-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
246 Kim Y, Stahl CC, Makramalla A, Olowokure OO, Ristagno RL, Dhar VK, Schoech MR, Chadalavada S, Latif T, Kharofa J, Bari K, Shah SA. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250-1258. [PMID: 29033224 DOI: 10.1016/j.surg.2017.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
247 Adwan H, Vogl TJ, Balaban Ü, Nour-eldin NA. Percutaneous Thermal Ablation Therapy of Hepatocellular Carcinoma (HCC): Microwave Ablation (MWA) versus Laser-Induced Thermotherapy (LITT). Diagnostics 2022;12:564. [DOI: 10.3390/diagnostics12030564] [Reference Citation Analysis]
248 Wigle TJ, Tsvetkova EV, Welch SA, Kim RB. DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics. 2019;11. [PMID: 31052357 DOI: 10.3390/pharmaceutics11050199] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
249 Lee J, Lee JH, Yoon H, Lee HJ, Jeon H, Nam J. Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath? Radiat Oncol J 2017;35:185-8. [PMID: 28712281 DOI: 10.3857/roj.2017.00262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
250 Deng B, Yang M, Wang M, Liu Z. Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20422. [PMID: 32481346 DOI: 10.1097/MD.0000000000020422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
251 Chacko S, Samanta S. A novel approach towards design, synthesis and evaluation of some Schiff base analogues of 2-aminopyridine and 2-aminobezothiazole against hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2017;89:162-76. [DOI: 10.1016/j.biopha.2017.01.108] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
252 Chu PY, Tung SL, Tsai KW, Shen FP, Chan SH. Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1843. [PMID: 32650537 DOI: 10.3390/cancers12071843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Chen Y, Song S, Zhang L, Zhang Y. Circular RNA hsa_circ_0091579 facilitates the Warburg effect and malignancy of hepatocellular carcinoma cells via the miR-624/H3F3B axis. Clin Transl Oncol 2021. [PMID: 33934291 DOI: 10.1007/s12094-021-02627-4] [Reference Citation Analysis]
254 Chen CY, Fang JY, Chen CC, Chuang WY, Leu YL, Ueng SH, Wei LS, Cheng SF, Hsueh C, Wang TH. 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression. Front Oncol 2020;10:1319. [PMID: 32850418 DOI: 10.3389/fonc.2020.01319] [Reference Citation Analysis]
255 Yasuda D, Ohe T, Takahashi K, Imamura R, Kojima H, Okabe T, Ichimura Y, Komatsu M, Yamamoto M, Nagano T, Mashino T. Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line. Free Radic Res. 2020;1-13. [PMID: 32075457 DOI: 10.1080/10715762.2020.1732955] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
256 Sun Y, Tsao R, Chen F, Li H, Peng H, Jiang L, Chen Y, Deng Z. The phenolic profiles of Radix Tetrastigma after solid phase extraction (SPE) and their antitumor effects and antioxidant activities in H22 tumor-bearing mice. Food Funct 2017;8:4014-27. [DOI: 10.1039/c7fo00769h] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]